SCHEMBL10029201

SCHEMBL10029201

Cc1cc(C=O)ccc1NC(=O)CS

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
TP53 P04637 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10029204 0.84 ALDH1A1 (0.67) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL6004294 0.83 POLB (0.52) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL7013927 0.80 ALDH1A1 (0.52) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL5805432 0.80 KMT2A (0.77) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL13569458 0.79 KMT2A (0.54) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL7069760 0.79 POLB (0.44) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL3437393 0.79 MEN1 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL7935570 0.78 ALDH1A1 (0.59) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL1509787 0.77 ALDH1A1 (0.51) MEN1KMT2AALDH1A1SMN1; SMN2HTT
SCHEMBL6005086 0.77 SMN1; SMN2 (0.69) MEN1KMT2AALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8552043-B2 N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors ARDEA BIOSCIENCES, INC. (US) 2013-10-08 US disclosed
US-20120077981-A1 N[S(4-ARYL-TRIAZOL-3-YL)ALPHA-MERCAPTOACETYL]-P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS ARDEA BIOSCIENCES INC. (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077981-A1 N[S(4-ARYL-TRIAZOL-3-YL)ALPHA-MERCAPTOACETYL]-P-AMINO BENZOIC ACIDS AS HIV REVERSE TRANSCRIPTASE INHIBITORS NQO2, NAT1, QPCT MEN1 4854/4885KMT2A 483/4885ALDH1A1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.